Keyword Search Year None202420232022202120202019201820172016 Jan 18, 2024 NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH Jan 09, 2024 NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement Jan 02, 2024 NeuroBo to Participate in Industry and Investor Conferences in January Pagination First page « first Previous page ‹ previous Page 1 Current page 2
Jan 18, 2024 NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH